New drug aims to speed up recovery from anesthesia muscle relaxants
NCT ID NCT07595393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests amogammadex sodium, a drug designed to reverse the effects of common muscle relaxants (rocuronium or vecuronium) used during surgery. About 64 adults having elective surgery will receive the drug at the end of their procedure. Researchers will measure how quickly muscle strength returns and monitor for any side effects. The goal is to find the best dose for future larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- amogammadex sodium
- What this could lead to
- If successful, this could provide a faster, safer way to reverse muscle relaxants after surgery, helping patients recover muscle strength more quickly.
- What could go wrong
- This is an early Phase 2 dose-finding study with only 64 participants. It may not show clear benefit or could have unexpected side effects. Results may not apply to all surgical patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REVERSING ROCURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.